Omar Kabbarah

2.7k total citations
42 papers, 1.5k citations indexed

About

Omar Kabbarah is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Omar Kabbarah has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Cancer Research and 14 papers in Molecular Biology. Recurrent topics in Omar Kabbarah's work include Colorectal Cancer Treatments and Studies (14 papers), Genetic factors in colorectal cancer (12 papers) and Cancer Genomics and Diagnostics (11 papers). Omar Kabbarah is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Genetic factors in colorectal cancer (12 papers) and Cancer Genomics and Diagnostics (11 papers). Omar Kabbarah collaborates with scholars based in United States, Australia and Belgium. Omar Kabbarah's co-authors include Xueping Qu, Lynda Chin, Heinz‐Josef Lenz, Federico Innocenti, Fang‐Shu Ou, Alan P. Venook, Charles D. Blanke, Donna Niedzwiecki, Tyler Zemla and Monica M. Bertagnolli and has published in prestigious journals such as Nature, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Omar Kabbarah

38 papers receiving 1.5k citations

Peers

Countries citing papers authored by Omar Kabbarah

Since Specialization

Citations

This map shows the geographic impact of Omar Kabbarah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Kabbarah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Kabbarah more than expected).

Fields of papers citing papers by Omar Kabbarah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Kabbarah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Kabbarah. The network helps show where Omar Kabbarah may publish in the future.

Co-authorship network of co-authors of Omar Kabbarah

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Kabbarah. A scholar is included among the top collaborators of Omar Kabbarah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Kabbarah. Omar Kabbarah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial 2024 ·Regular and Young Investigator Award Abstracts ·Ji Yun Kim, (unknown), José Luís Braga de Aquino, Chunyou Mao, Karim Mrouj, (unknown), Scott Kopetz, Yong Sang Hong, Jacques Mizrahi, Joon Haeng Rhee, (unknown), Daniel DiRenzo, Matthew J. Walters, (unknown), (unknown), Omar Kabbarah	0
2	HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 2024 ·Journal of Clinical Oncology ·Francesca Battaglin, Fang‐Shu Ou, Xueping Qu, Howard S. Höchster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, (unknown), Tyler Zemla, Charles D. Blanke, Alan P. Venook, Omar Kabbarah, Heinz‐Josef Lenz, Federico Innocenti	9
3	Abstract C007: Quemliclustat (CD73 Inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial 2024 ·Cancer Research ·Ji Yun Kim, Ning Wang, Benjamin R. Weeder, (unknown), Karim Mrouj, José Luís Braga de Aquino, Xian He, Eileen M. O’Reilly, Shubham Pant, Gulam A. Manji, Zev A. Wainberg, Joon Haeng Rhee, (unknown), Daniel DiRenzo, Matthew J. Walters, (unknown), (unknown), Omar Kabbarah	1
4	DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations 2023 ·Journal of Clinical Oncology ·Federico Innocenti, (unknown), Xueping Qu, Fang‐Shu Ou, Omar Kabbarah, Charles D. Blanke, Alan P. Venook, Heinz‐Josef Lenz, Naim U. Rashid	5
5	CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy 2022 ·Cancer Research Communications ·(unknown), (unknown), (unknown), Christopher W. Szeto, Renyi Wu, (unknown), Fang Xu, (unknown), Lei Wang, Lina Wang, Jing Li, Qiuping Ye, (unknown), (unknown), Omar Kabbarah, (unknown)	10
6	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer 2022 ·Nature Communications ·Radia Marie Johnson, Xueping Qu, (unknown), Ling‐Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang‐Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, (unknown), Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz‐Josef Lenz, Carlos Bais	24
7	Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. 2022 ·Journal of Clinical Oncology ·Wu Zhang, Joshua Millstein, (unknown), Fang‐Shu Ou, Federico Innocenti, (unknown), Shivani Soni, Shannon M. Mumenthaler, (unknown), Priya Jayachandran, Monica M. Bertagnolli, Dustin A. Deming, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Alan P. Venook, Omar Kabbarah, Francesca Battaglin, Heinz‐Josef Lenz	0
8	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B 2021 ·PLoS ONE ·Anneleen Daemen, (unknown), Thomas Sandmann, Congfen Li, Linda J.W. Bosch, William O’Gorman, Yijin Li, Amelia Au‐Yeung, Chikara Takahashi, Omar Kabbarah, Richard Bourgon, Priti S. Hegde, Carlos Bais, Meghna Das Thakur	4
9	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer 2019 ·Clinical Cancer Research ·Robert Piskol, Ling Huw, Ismail Sergin, (unknown), Zora Modrušan, Doris Kim, Noelyn M. Kljavin, Rachel Tam, Rajesh Patel, (unknown), Elicia Penuel, Xueping Qu, Hartmut Koeppen, Teiko Sumiyoshi, Frédéric J. de Sauvage, Mark R. Lackner, Felipe de Sousa e Melo, Omar Kabbarah	40
10	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma 2019 ·Investigational New Drugs ·Shahneen Sandhu, Catriona M. McNeil, Patricia LoRusso, Manish R. Patel, Omar Kabbarah, Chunze Li, Sandra Sanabria, W. Michael Flanagan, Ru‐Fang Yeh, Flávia Brunstein, (unknown), Rodney J. Hicks, Vanessa Lemahieu, Raymond D. Meng, Omid Hamid, Jeffrey R. Infante	23
11	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance) 2019 ·Journal of Clinical Oncology ·Heinz‐Josef Lenz, Fang‐Shu Ou, Alan P. Venook, Howard S. Höchster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Charles D. Blanke, Tyler Zemla, Xueping Qu, Pratyaksha Wirapati, Sabine Tejpar, Federico Innocenti, Omar Kabbarah	169
12	Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 2015 ·Cancer Research ·Daniel C. Danila, Howard I. Scher, Edith Szafer‐Glusman, (unknown), (unknown), Martin Fleisher, Nicole A. Schreiber, Kristen Curtis, Houston Gilbert, Daniel Maslyar, Bernard M. Fine, Ron Firestein, Michael Mamounas, Mark R. Lackner, Omar Kabbarah	1
13	Genomic landscape of metastatic colorectal cancer 2014 ·Nature Communications ·Josien Haan, Mariëtte Labots, Christian Rausch, Miriam Koopman, Jolien Tol, Leonie J. Mekenkamp, Mark A. van de Wiel, (unknown), Hendrik F. van Essen, Nicole C.T. van Grieken, Quirinus J.M. Voorham, Linda J.W. Bosch, Xueping Qu, Omar Kabbarah, Henk M.W. Verheul, Irıs D. Nagtegaal, Cornelis J.A. Punt, Bauke Ylstra, Gerrit A. Meijer	45
14	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer 2009 ·Nature ·Kenneth L. Scott, Omar Kabbarah, Mei‐Chih Liang, Elena V. Ivanova, Valsamo Anagnostou, Joyce C. Wu, Sabin Dhakal, Min Wu, Shujuan Chen, Tamar Y. Feinberg, Joseph Huang, Abdel Saci, Hans R. Widlund, David E. Fisher, Yonghong Xiao, David L. Rimm, Alexei Protopopov, Kwok‐Kin Wong, Lynda Chin	297
15	Advances in malignant melanoma: genetic insights from mouse and man 2006 ·Frontiers in bioscience ·Omar Kabbarah	11
16	Transcriptional profiling endometrial carcinomas microdissected from DES‐treated mice identifies changes in gene expression associated with estrogenic tumor promotion 2006 ·International Journal of Cancer ·Omar Kabbarah, Mary A. Mallon, John D. Pfeifer, Paul J. Goodfellow	8
17	Revealing the genomic heterogeneity of melanoma 2005 ·Cancer Cell ·Omar Kabbarah, Lynda Chin	32
18	Diethylstilbestrol effects and lymphomagenesis in Mlh1‐deficient mice 2005 ·International Journal of Cancer ·Omar Kabbarah, (unknown), Mary A. Mallon, (unknown), Mingyu Fan, John D. Pfeifer, Darryl Shibata, David H. Gutmann, Paul J. Goodfellow	8
19	A panel of repeat markers for detection of microsatellite instability in murine tumors 2003 ·Molecular Carcinogenesis ·Omar Kabbarah, Mary A. Mallon, John D. Pfeifer, Winfried Edelmann, Raju Kucherlapati, Paul J. Goodfellow	27
20	Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice 2003 ·Oncogene ·David H. Gutmann, (unknown), Omar Kabbarah, Nicolé M. Hedrick, Sandra Dudley, Paul J. Goodfellow, R. Michael Liskay	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact